Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

BPD app trial halted: what happened?

NCT ID NCT06601907

Symptom relief Sponsor: Gaia AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested alivis, a smartphone app that teaches coping skills for borderline personality disorder (BPD). It was designed for people aged 18-65 with BPD, who used the app alongside their usual treatment. The goal was to see if the app reduces BPD symptoms, depression, and anxiety. However, the trial was terminated early, so we don't have clear results on its effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
alivis digital health application
What this could lead to
If it had succeeded, this could point toward a convenient, app-based way to help manage BPD symptoms alongside usual care.
What could go wrong
The trial was terminated early, so results are not available. Digital interventions may not work for everyone, and this was an unguided program.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

286 people

The number who actually took part.

Started

Sep 2024

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of BPD * Borderline severity score (cut-off) of ≥ 1.07 on the BSL-23 * Stable treatment (e.g., psychotherapy, medication, no treatment) for at least 30 days at the time of inclusion * Consent to emergency plan for suicidal crises * Consent to participation * Sufficient knowledge of the German language Exclusion Criteria: * Plans to change treatment (e.g., psychotherapy, medication) in the upcoming 6 months after inclusion * Comorbid diagnosis of substance use disorder * Lifetime diagnosis of psychotic disorder like schizophrenia or schizoaffective disorder (except non-transitory paranoid ideas that can be concomitant with BPD and in which the ability to test reality is mostly preserved) * Diagnosis of a physical condition that can cause serious psychiatric symptoms * Acute decompensation of mental health symptoms, e.g. acute manic state or acute suicidality * BMI \< 15 * Current psychiatric day-care or inpatient treatment * Prior use of the digital intervention priovi

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Borderline personality disorder (BPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

borderline personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Borderline personality disorder (BPD)

Contacts and locations

Locations

  • GAIA

    Hamburg, 22085, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.